Investors

Press Releases

Press Releases

May 8, 2019
REDWOOD CITY, Calif. , May 08, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today reported financial results for the first quarter ended March 31, 2019.
February 11, 2019
-- 55% (6/11) response rate by UCT in Xolair Refractory CSU patients -- -- 49% reduction in UAS7 in Xolair Refractory CSU patients -- -- 77% (10/13) complete hive response by HSS7 in Xolair Naïve CSU patients -- -- 54% (7/13) complete itch response by ISS7 in Xolair Naïve CSU patients -- -- 54%
February 4, 2019
REDWOOD CITY, Calif. , Feb. 04, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced that it will host an Investor Day on February 19 th starting at 12:00 pm ET in New York City

Copyright West LLC. Minimum 15 minutes delayed.